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Abstract
Purpose The worldwide prevalence of human papillomavirus
(HPV) infection is estimated at 9–13 %. Persistent infection
can lead to the development of malignant and nonmalignant
diseases. Low-risk HPV types are mostly associated with
benign lesions such as anogenital warts. In the present sys-
tematic review, we examined the impact of smoking on HPV
infection and the development of anogenital warts,
respectively.
Methods A systematic literature search was performed using
MEDLINE database for peer-reviewed articles published
from January 01, 1985 to November 30, 2013. Pooled rates
of HPV prevalence were compared using the χ2 test.
Results In both genders, smoking is associated with higher
incidence and prevalence rates for HPVinfection, whereas the
latter responds to a dose-effect relationship. The overall HPV
prevalence for smoking patients was 48.2 versus 37. 5 % for
nonsmoking patients (p<0.001) (odds ratio (OR)=1.5, 95 %
confidence interval (CI) 1.4–1.7). Smoking does also increase
persistence rates for high-risk HPV infection, while this cor-
relation is debatable for low-risk HPV. The incidence and
recurrence rates of anogenital warts are significantly increased
in smokers.
Conclusions Most current data demonstrate an association
between smoking, increased anogenital HPV infection, and
development of anogenital warts. These data add to the long
list of reasons for making smoking cessation a keystone of
patient health.
Keywords Smoking . Human papillomavirus . Anogenital
warts
Introduction
According to the World Health Organization (WHO), 630
million people are infected with genital human papillomavirus
(HPV), resulting in an estimated worldwide prevalence of 9–
13 % [1, 2]. HPV is transmitted via genital contact and is the
most common sexually transmitted infection worldwide [3, 4].
There is no consensus on a gender-specific risk of acquiring
HPV [5]. Whereas at least 40 % of HPVinfections are asymp-
tomatic and transient, with subsequent clearance by the im-
mune system, some infections persist [2, 5]. Persistent infec-
tion can lead to the development of malignant and premalig-
nant or nonmalignant diseases, so-called “anal intraepithelial
neoplasia” (AIN). Over 100 HPV types have been identified.
Approximately 40 of these affect the anogenital region [2, 6].
HPV infections are detected by collecting material with
brushes or swabs, followed by polymerase chain reac-
tion analysis, genotyping, and HPV classification ac-
cording to their risk of causing cervical cancer [2]:
Low-risk HPV types are mostly associated with benign
lesions such as anogenital warts (AIN grade I), and
high-risk or oncogenic types are also associated with
cancers and their precursors (AIN grade II/III) [6]. More
than 90 % of anogenital warts are caused by low-risk
HPV types 6 and 11 [7, 8]. Infected basal cells move
toward the surface layer, where they ultimately develop
to anogenital warts [2]. The worldwide prevalence of
visible anogenital warts ranges from 0.13 to 5.1 % [9].
These may regress spontaneously, with reported
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clearance rates varying widely from 0 to 55 % [10-12].
However, even with therapy (topical, surgical, and/or
destructive), the recurrence rate within 3 months is
25–67 % [10].
Apart from genital contact, risk factors for HPVacquisition
include younger age, early coitarche, number of lifetime sex-
ual partners, failure to use condoms consistently, marital sta-
tus, history of sexually transmitted infections, immunosup-
pression (including patients with human immunodeficiency
virus), history of other HPV-mediated neoplasia, and low
socioeconomic status [13, 4]. Furthermore, smoking is postu-
lated to be an additional risk factor, due to increased suscep-
tibility to the acquisition of HPV [14].
In the present systematic review, we examined the impact
of smoking on the incidence, persistence, and prevalence of
HPVand of anogenital warts.
Methods
A systematic literature search was performed using
MEDLINE database for peer-reviewed articles published
in English. The search was carried out for articles
published from January 01, 1985 to November 30,
2013, using the following keywords: smoking AND
human papillomavirus AND/OR incidence AND/OR
prevalence AND/OR persistence AND/OR condylomata
acuminata AND/OR anogenital warts AND/OR genital
warts. The references in the identified articles were also
reviewed. Titles and abstracts, when available, were
scrutinized to select relevant studies addressing the re-
lation of smoking and HPV infection and/or the occur-
rence of anogenital warts. All studies addressing the
relation in the abstract and/or the full text manuscript
were subsequently included. Case reports, letters to ed-
itors, and review articles were excluded. In addition,
studies restricted to patients with cervical or AIN and
cervical or anal cancer were excluded. Furthermore,
studies examining HPV infection or warts in other re-
gions than the genital or anal were excluded.
Pooled rates of HPV prevalence were compared be-
tween smoking and nonsmoking patients, using the χ2
test. For this analysis, only prospective studies were
included. As time intervals for incidence and persistence
were different between studies with an analysis of dif-
ferent HPV types, comparison of these pooled rates was
not practicable. To assess the clinical significance of
differences in prevalence rates between smoking and
nonsmoking patients, the 95 % confidence interval
(CI) for the difference was derived. Statistical Package
for Social Sciences (SPSS Windows) version 21.0
(SPSS, Chicago, IL) was used for all analyses.
Results
Incidence of HPV
Fifteen studies (14 prospective and one retrospective) are
available on the impact of smoking on the incidence of HPV
[15-29]. The retrospective study—including 1,880 patients—
did not reveal an association [17]. Of the 14 prospective
studies, 12 investigated genital [15, 16, 18-26, 29], one
anogenital [27], and one solely anal [28] HPVinfections. Nine
of these 14 studies demonstrated a significant [15, 16, 18, 19,
21, 22, 24, 26, 27], one a nonsignificant [20], and four no
association between HPV incidence and smoking (Table 1)
[28, 30, 25, 29].
A gender-specific analysis revealed that three out of four
prospective studies including a total of 5,376 male patients
found a significant association between smoking and the
incidence of HPV [16, 27, 21]. Only one prospective study
with 374 male patients did not reveal an association [23].
Similarly, six out of ten prospective studies comparing
27,508 smoking and nonsmoking female patients found a
significant association [15, 18, 19, 22, 24, 26]. Additionally,
Oh et al. found a statistically nonsignificant trend toward an
association among female patients [20]. Three remaining pro-
spective studies, including 1,339 female patients, did not
reveal an association [28, 25, 29].
Whereas the above-mentioned studies focused on the as-
sociation of HPVincidence to current smoking, Partridge et al.
found an association solely between past smoking and HPV
infection (hazard ratio (HR)=1.6, 95 % CI 1.1–2.4) [21].
Persistence of HPV
Thirteen prospective studies including a total of 18,529 pa-
tients investigated the impact of smoking on the persistence
rate of anogenital HPV during time intervals of 4 [31], 6 [27,
32-34, 23, 35, 16], or more [36, 37, 20, 38] months (one
missing specification of time interval [39]). Nevertheless, the
association between smoking and the persistence of HPV is
not conclusive with regard to the number of patients in the two
groups: Eleven of these 13 studies, including a total of 10,503
patients, found a statistically significant association (seven
studies [27, 32, 33, 36, 31, 39, 38]) between HPV persistence
and smoking or a trend (four studies [16, 20, 34, 23]) toward
higher rates among smokers compared to nonsmokers [16, 27,
32, 33, 36, 31, 20, 34, 23, 39, 38]. Maucort-Boulch et al. even
found a dose-effect relationship: Smoking >20 cigarettes per
day was associated with a significantly increased risk of
persistence of HPVinfection among women, when compared
with women who smoked <10 cigarettes per day (odds ratio
(OR)=1.43, 95 % CI 1.02–2.01) [33]. The remaining two
studies prospectively included a total of 8,026 patients but
could not establish a positive relationship between smoking
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and the persistence rate of HPV [37, 35]. Interestingly, Ho
et al. even found that smoking >5 cigarettes per day was
protective against persistent HPV infection (OR=0.3, 95 %
CI 0.2–0.7) [35].
Table 1 Summary of all prospective studies evaluating the association between the incidence of HPVand smoking
Author Publication
year
Study
design
Population
(sex,
number of
patients
included)
Localization Association
with
smoking
HPV
incidence in
nonsmoking
subjects
HPV
incidence in
currently
smoking
subjects
OR or HR
for
currently
smoking
subjects
Specification of the
association
Clarke
et al.
[15]
2013 Prospective Female, n=
3,737
Genital Yes 1,491/3,225
(46.2 %)
[50.7 months]
317/499
(63.5 %)
[50.7 months]
HR=1.2;
95 % CI
1.0–1.3
Evaluation of high-risk
HPV infection
Schabath
et al.
[16]
2013 Prospective Male, n=
4,026
Genital Yes 812/2,326
(34.9 %)
[12 months]
399/948
(42.1 %)
[12 months]
HR=1.2;
95 % CI
1.0–1.5
Significantly higher
association for current
smokers compared to
former and never
smokers
Nyitray
et al.
[27]
2011 Prospective Male, n=
1,110
Anogenital (Yes) – – – Association in bivariate
analysis among men
who have sex with
women
Nielsen
et al.
[18]
2009 Prospective Female, n=
7,454
Genital Yes – – OR=1.5;
95 % CI
1.2–1.9
Association for
acquiring a single
high-risk HPV
infection (≥10
cigarettes per day)
Sarian
et al.
[19]
2009 Prospective Female, n=
12,114
Genital Yes – – OR=1.6;
95 % CI
1.2–2.1
Evaluation of high-risk
HPV infection
Goodman
et al.
[28]
2008 Prospective Female, n=
431
Anal No 137/276
(49.6 %)
[16 months]
29/61
(47.5 %)
[16 months]
OR=0.9;
95 % CI
0.5–1.6
Oh et al.
[20]
2008 Prospective Female, n=
197
Genital (Yes) 16/131
(12.2 %)
[18 months]
5/12 (41.7 %)
[18 months]
OR=3.3;
95 % CI
0.7–
14.6
Statistically
nonsignificant trend
Partridge
et al.
[21]
2007 Prospective Male, n=
240
Genital Yes – – HR=1.0;
95 % CI
0.4–2.2
Association with past
smoking but not with
current smoking
Syrjänen
et al.
[22]
2007 Prospective Female, n=
3187
Genital Yes – – OR=1.5;
95 % CI
1.1–2.1
Evaluation of high-risk
HPV infection
Kjaer
et al.
[23]
2005 Prospective Male, n=
374
Genital No 17/102
(16.7 %)
[7 months]
6/42 (14.3 %)
[7 months]
OR=0.6;
95 % CI
0.2–2.0
Minkoff
et al.
[24]
2004 Prospective Female, n=
2293
Genital (Yes) – – – Association in HIV-
infected but not in
HIV-uninfected
women
Sellors
et al.
[25]
2003 Prospective Female, n=
307
Genital No 19/178
(10.7 %)
[14 months]
9/72 (12.5 %)
[14 months]
OR=0.6;
95 % CI
0.2–1.9
Evaluation of high-risk
HPV infection
Winer
et al.
[26]
2003 Prospective Female, n=
603
Genital Yes – – HR=1.5;
95 % CI
1.0–2.3
Association with current
smoking
Moscicki
et al.
[29]
2001 Prospective Female, n=
601
Genital No – – –
OR odds ratio, HR hazard ratio
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Prevalence of HPV
With respect to the prevalence of anogenital HPV, most stud-
ies showed an association with smoking for both men and
women. Forty-seven studies (four prospective [40, 19, 41, 24],
one retrospective [42], and 42 cross-sectional [43-68, 14,
69-83] studies)—including a total of 83,480 patients—found
a significant association (35 studies [19, 40-44, 46, 48-53,
55-59, 61-64, 66-68, 14, 69-71, 75-77, 79, 80, 83]) with
smoking or a trend (12 studies [24, 45, 47, 54, 65, 72-74,
60, 78, 81, 82]) toward an association, whereas 16 studies
(one prospective [84] and 15 cross-sectional [17, 85-98] stud-
ies)—with a total of 12,188 patients—did not. Four out of five
prospective studies—including 19,581 patients—found a sig-
nificant association (three studies) between HPV prevalence
and smoking or a trend (one study) toward higher rates among
smokers compared to nonsmokers (Table 2) [40, 19, 41, 24].
The remaining prospective study with 576 patients did not
reveal an association [84].
A statistical analysis of all prospective studies evaluating
association between the prevalence of HPV and smoking
showed that the overall HPV prevalence for smoking patients
was 48.2 versus 37.5 % for nonsmoking patients (p<0.001)
(OR=1.5, 95 % CI 1.4–1.7). For female patients only, the
prevalence was 40.8 % for smokers versus 25.2 % for non-
smokers (p<0.001) (OR=2.0, 95 % CI 1.8–2.3) and for male
patients 68.2 versus 63.2 % (p=0.006) (OR=1.2, 95 % CI
1.1–1.5).
There are ten studies comparing current with past smoking
with regard to the prevalence of HPV [49, 51, 40, 61, 19, 14,
69, 72, 77, 90]. Except for one study, no impact of past
smoking on the prevalence of HPV was shown [49, 51, 40,
61, 19, 14, 69, 72, 77].
Four cross-sectional studies among current smokers
showed increasing prevalence of HPV with the number of
cigarettes smoked [49, 50, 14, 69]. Nielson et al. found a
stronger association between HPV detection and smoking
≥10 cigarettes than for smoking <10 cigarettes per day
(OR=2.3, 95 % CI 1.0–5.3) [69]. In contrast, Roura et al.
and Schabath et al. did not find any impact of the intensity of
smoking on the prevalence of HPV [51, 40].
High-risk HPV
Four prospective studies focused on the incidence of high-risk
HPV infection [15, 19, 22, 18]. These investigators
Table 2 Summary of all prospective studies evaluating the association between the prevalence of HPVand smoking
Author Publication
year
Study
design
Population
(sex,
number of
patients
included)
Localization Association
with
smoking
HPV
prevalence
in
nonsmoking
subjects
HPV
prevalence
in currently
smoking
subjects
OR or HR
for
currently
smoking
subjects
Specification of the
association
Schabath
et al.
[40]
2012 Prospective Male, n=
4,054
Genital Yes 1,485/2,348
(63.2 %)
655/960
(68.2 %)
OR=1.2,
95 %
CI 1.0–
1.4
Association with current but
not past smokers. No
association between
intensity of smoking and
HPV prevalence
Sarian et al.
[19]
2009 Prospective Female, n=
12,114
Genital Yes 444/2,699
(16.5 %)
215/990
(21.7 %)
OR=1.6,
95 %
CI 1.2–
2.1
Evaluation of high-risk HPV
infection. Association
with current but not past
smokers
Kliucinskas
et al.
[41]
2006 Prospective Female, n=
1,120
Genital Yes 109/892
(12.2 %)
25/128
(19.5 %)
OR=1.8,
95 %
CI 1.2–
2.8
Evaluation of high-risk HPV
infection
Minkoff
et al.
[24]
2004 Prospective Female, n=
2,293
Genital (Yes) 516/966
(53.4 %)
735/1,294
(56.8 %)
OR=1.1,
95 %
CI 1.0–
1.4
Association in HIV-infected
but not in HIV-uninfected
women
Feldman
et al.
[84]
1997 Prospective Female, n=
576
Genital No 174/370
(47.0 %)
93/206
(45.1 %)
OR=0.9,
95 %
CI 0.7–
1.3
Total 2,728/7,275
(37.5%)
1,723/
3,578
(48.2%)
OR=1.5,
95%
CI 1.4–
1.7
OR odds ratio, HR hazard ratio
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consistently found a significant association between smoking
and high-risk HPV incidence.
Regarding persistence of high-risk HPVinfection, three out
of four prospective studies with a total of 827 patients revealed
a significant association with smoking [32, 39, 38], whereas
one study with 7,418 patients did not [37].
An analysis of HPV types in female patients revealed no
significant difference in prevalence of high- or low-risk HPV
genotypes when comparing female smokers to nonsmokers
[99]. In two prospective studies including a total of 13,234
patients, a significant impact of smoking on the prevalence of
high-risk HPV was found [19, 41].
Development of anogenital warts
Smoking has been shown to significantly increase the
incidence of anogenital warts (Table 3). The risk of
developing anogenital warts increases with the number
Table 3 Summary of all published studies evaluating the association between the incidence of anogenital warts and smoking
Author Publication
year
Study design Population
(sex,
number of
patients
included)
Localization Association
with
smoking
Incidence of
anogenital
warts in
nonsmoking
subjects
Incidence of
anogenital
warts in
currently
smoking
subjects
OR or HR
for
currently
smoking
subjects
Specification of the
association
Massad
et al.
[103]
2011 Prospective Female,
n=3766
Genital Yes – – HR=1.8,
95 %
CI 1.4–
2.4
Association with current
but not with former
smoking
Wiley
et al.
[113]
2009 Prospective Male, n=
2835
Genital Yes – – –
Massad
et al.
[104]
2004 Prospective Female,
n=2031
Genital Yes – – – Association with current
but not with former
smoking
Feldman
et al.
[84]
1997 Prospective Female,
n=576
Genital Yes – – –
Hansen
et al.
[102]
2010 Retrospective Female,
n=
58094
Genital Yes – – HR=1.3,
95 %
CI 1.2–
1.4.
Increasing risk with
increasing number of
cigarettes smoked per
day
Kjaer
et al.
[114]
2007 Retrospective Female,
n=
69147
Genital Yes 2,936/35,799
(8.2 %)
2,251/15,965
(14.1 %)
OR=1.1,
95 %
CI 1.0–
1.2
Association with smoking
for >59 pack-years
Wen
et al.
[13]
1999 Retrospective Male and
female,
n=1954
Genital Yes 89/631
(14.1 %)
154/644
(23.9 %)
OR=1.9,
95 %
CI 1.0–
2.3
Smokers of more than 10
cigarettes per day were
twice as likely to have
genital warts as were
nonsmokers
Habel
et al.
[106]
1998 Retrospective Female,
n=282
Anogenital (Yes) 45/118
(38.1 %)
35/67
(52.2 %)
OR=1.8,
95 %
CI 1.0–
3.3
Statistically nonsignificant
association
Munk
et al.
[100]
1997 Retrospective Female,
n=
10838
Genital Yes – – OR=1.5,
95 %
CI 1.2–
1.8
Increasing risk with
increasing pack-years
of cigarette smoking
Brisson
et al.
[101]
1988 Retrospective Female,
n=520
Genital Yes – – – Increasing risk with
increasing number of
cigarettes smoked per
day
Daling
et al.
[115]
1986 Retrospective Female,
n=245
Anogenital Yes – – –
OR odds ratio, HR hazard ratio
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of cigarettes smoked per day and the number of pack-
years [13, 100-102]. However, this association only
applies to current but not to past smoking [103, 104].
Luu et al. investigated the impact of current smoking on
the size of anal warts but failed to find a relationship
[105]. Smoking for 10 or more years has been found to
increase the risk of recurrent genital warts (relative risk
(RR)=4.5, 95 % CI 1.4–13.8) [106].
Discussion
In both genders, smoking is associated with higher
incidence and prevalence rates for HPV infection,
whereas the latter responds to a dose-effect relationship.
Smoking does also increase persistence rates for high-
risk HPV infection, while this correlation is debatable
for low-risk HPV. The incidence and recurrence rates of
anogenital warts are significantly increased in current
smokers.
Smoking has deleterious effects on systemic and local
immunity, as it suppresses both cell-mediated and hu-
moral immune responses, which might lead to the pres-
ent finding of increased susceptibility to HPV infection
and development of anogenital warts [107]. Nicotine,
the addictive substance in cigarette smoke, has been
shown to be the main immunosuppressive constituent
of cigarette smoke [107]. Moreover, smoking has been
found to increase metaplasia and DNA damage in var-
ious tissues [108-111].
Although most studies adjusted for sexual behavior,
unmeasured high-risk sexual behavior might be a poten-
tially important confounder in the association between
smoking and the incidence of HPV infection [16, 15,
26]. This is supported by Herrero et al., who found that
sex with multiple partners is more prevalent among
smokers [112].
The prevalence of HPV infection seems to decrease in
patients who quit smoking, but the time period after which
nonsmoker levels are reached is not yet clear.
The association of smoking with HPVinfection and devel-
opment of anogenital warts, respectively, is well supported by
current data. However, the cascade from HPVinfection to the
development of anogenital warts is still not well understood.
Furthermore, prospective data on the impact of smoking on
the spontaneous recovery rate of anogenital warts are still
lacking.
Studies are more often performed for female than male
patients, probably due to regular gynecologic controls. On
the other hand, comparison of the studies did not reveal gender
differences in the impact of smoking.
Conclusion
Most current data demonstrate an association between
smoking, increased anogenital HPV infection, and develop-
ment of anogenital warts. These data add to the long list of
reasons for making smoking cessation a keystone of patient
health.
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